The study, published in European Urology, examined whether conventional findings in prostate tissue removed during surgery could predict the effectiveness of androgen-deprivation therapy when combined with postoperative radiotherapy. The investigators found that these features were strongly associated with a patient’s overall prognosis, but they did not identify a subgroup that gained a greater survival advantage from hormone therapy.

The distinction is clinically important. After prostatectomy, some men have detectable or rising prostate-specific antigen, or PSA, or pathological evidence suggesting that cancer could return. Radiation therapy may then be directed at the surgical bed and nearby tissues. Hormone therapy, also called androgen-deprivation therapy, suppresses testosterone and other androgen signals that can stimulate prostate cancer cells. Although the combination can improve outcomes in selected patients, hormone therapy may also cause hot flashes, fatigue, sexual dysfunction, loss of bone density, weight gain and metabolic changes.

To investigate whether pathology could guide that decision, the research team assembled individual patient data from five phase 3 randomized clinical trials. Together, the studies included 4,781 men who had undergone prostate cancer surgery and subsequently received radiation therapy, either alone or with hormone therapy. Pooling patient-level data allowed the researchers to examine treatment effects across clinically relevant subgroups rather than relying only on broad results from separate trials.

The investigators created an adverse feature count based on four pathological findings associated with aggressive disease. These included Grade Group 4 or 5 cancer, invasion of the seminal vesicles, extension of cancer beyond the prostate and positive surgical margins, in which malignant cells are found at the edge of the removed tissue. Each patient received a score from zero to four according to the number of features present.

The results confirmed that the score was prognostic. In other words, men with more adverse features generally faced a higher risk of cancer spreading, or metastasizing, and a higher risk of death. High-grade tumors reflect more abnormal cellular behavior, while extraprostatic extension and seminal vesicle invasion indicate that the tumor has penetrated beyond the prostate’s main boundaries. Positive margins suggest that microscopic disease may remain after surgery.

Yet the same score was not predictive of treatment benefit. Statistical analyses found no evidence that men with multiple adverse pathological features experienced a larger improvement in overall survival or metastasis-free survival when hormone therapy was added to radiation. Patients with fewer risk factors did not appear to be the only group benefiting, nor did those with the most aggressive pathological profiles show a clearly amplified response.

This finding illustrates a central concept in precision oncology. A prognostic biomarker estimates how a disease is likely to behave regardless of treatment, while a predictive biomarker indicates whether a particular therapy is more or less likely to work. The pathological features examined in this analysis functioned as prognostic markers, but they did not demonstrate the treatment-interaction effect required to guide hormone therapy decisions.

The pattern remained consistent among men whose PSA level was 0.5 nanograms per milliliter or less before radiation. Previous research has suggested that the overall advantage of adding hormone therapy may be limited in this setting, making the question of patient selection especially relevant. The new analysis indicates that traditional postoperative pathology does not solve that selection problem, even when several high-risk features are present.

“These findings highlight an important distinction between predicting risk and predicting treatment benefit,” said lead investigator Dr. Amar Kishan, professor and executive vice chair of radiation oncology at the David Geffen School of Medicine at UCLA. Kishan said the results point to the need for molecular biomarkers capable of revealing tumor biology and identifying which patients are genuinely sensitive to hormone suppression. Such tools could help clinicians intensify treatment for men likely to benefit while sparing others from avoidable toxicity.

The study’s senior author was Dr. Daniel Spratt of University Hospitals Seidman Cancer Center and Case Western Reserve University. The UCLA research team included Tahmineh Romero-Kalbasi, Dr. Michael Steinberg, Dr. Luca Valle, Dr. Kekoa Taparra, Dr. Matthew J. Farrell, Dr. Matthew Rettig, Dr. Adam Singer, Dr. Nikita Baclig, Dr. Robert Reiter, Dr. Scott Eggener, Dr. Wayne Brisbane and Dr. Nicholas Nickols. The investigators’ conclusion is not that pathology has lost its value, but that risk classification alone cannot determine treatment response. Future approaches may combine pathological assessment with genomic signatures, immune markers, imaging and other molecular measurements to make postoperative prostate cancer treatment more precise.

Subject of Research: Prostate cancer treatment response after surgery, with a focus on postoperative radiation therapy and hormone therapy.

News Publication Date: Not provided.

Web References: UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer ; Dr. Amar Kishan: https://www.uclahealth.org/providers/amar-kishan

References: European Urology, DOI: 10.1016/j.eururo.2026.07.013

Keywords: Prostate cancer, prostate tumors, radiation therapy, hormone therapy, androgen-deprivation therapy, prostatectomy, pathological risk factors, metastasis-free survival, overall survival, cancer biomarkers, precision oncology, clinical trials, UCLA Health

Hormone therapy, also known as androgen deprivation therapy (ADT), has traditionally been used to suppress testosterone’s influence, as testosterone is a key driver of prostate cancer cell growth. While previous clinical trials have affirmed hormone therapy’s benefit in men with intact prostates undergoing radiotherapy, the efficacy of this approach in the post-surgical setting has remained inconclusive until now. The UCLA-led investigation specifically delves into this uncertainty by analyzing data from over 6,000 men across six randomized controlled trials, employing a sophisticated individual patient data meta-analysis methodology through the MARCAP Consortium.

The researchers meticulously stratified patients based on their PSA levels measured immediately before radiotherapy initiation following prostatectomy. Their detailed analyses reveal that men exhibiting low PSA levels (≤0.5 ng/mL) before radiation treatment do not derive any appreciable overall survival advantage from the addition of hormone therapy, regardless of whether it is administered short-term or long-term. This finding challenges previously held assumptions and highlights the potent efficacy of radiotherapy alone in controlling microscopic residual disease in low-PSA patients, suggesting a potential pause in prescribing hormone therapy in this subgroup.

Conversely, men with elevated PSA levels prior to commencing radiotherapy seem to benefit moderately from hormone therapy. For these higher-risk individuals, hormone treatment not only extends overall survival but also reduces the likelihood of metastatic disease, a critical factor impacting quality of life and long-term prognosis. These insights carve a pathway toward more personalized prostate cancer treatment protocols, ensuring that hormone therapy is reserved primarily for those patients who stand to gain the most while sparing others from unnecessary side effects.

One of the study’s strengths lies in its nuanced examination of hormone therapy duration. The investigation assessed short-term treatment lasting between four and six months alongside long-term administration spanning up to two years. Interestingly, short-term hormone therapy, while not significantly improving overall survival, did marginally decrease metastatic risk. Long-term therapy offered a slight survival benefit for patients with higher PSA pre-radiotherapy but was not conclusively superior to short-term therapy in improving mortality outcomes. This crucial distinction may influence clinical decisions regarding the length of hormone therapy required to optimize patient outcomes, balancing efficacy with quality of life considerations.

The team’s extensive follow-up period averaging nine years provided robust data for evaluating long-term effects, allowing for a comprehensive understanding of survival, recurrence, and metastasis trends over time. Such prolonged observation underscores the rigor and depth of the research, offering a rare window into the enduring impacts of combining hormone therapy with radiotherapy after prostatectomy. This long-term perspective is essential for guiding treatment paradigms in prostate cancer, a disease characterized by variable and often protracted clinical courses.

Importantly, the research underscores the significant side-effect burden associated with hormone therapy, which includes debilitating fatigue, hot flashes, sexual dysfunction, weight gain, and metabolic derangements that elevate cardiovascular risk. These adverse effects can profoundly diminish a patient’s quality of life, reinforcing the imperative to precisely identify those who truly benefit from hormone therapy. The findings advocate for a careful risk-benefit assessment, steering away from blanket hormone therapy use toward more judicious, personalized care strategies.

Dr. Amar Kishan, the study’s lead author and a radiation oncology expert at UCLA’s David Geffen School of Medicine, emphasized the transformative potential of these findings. He highlighted that precise patient stratification based on PSA levels prior to radiation could serve as a pivotal biomarker in clinical decision-making, allowing physicians to spare men with low PSA from unnecessary and potentially harmful treatments. This approach aligns with the broader trend in oncology toward de-escalation of therapy where appropriate, minimizing harm without compromising efficacy.

The researchers utilized a meta-analytic approach that pooled individual patient data across multiple randomized controlled trials, an advanced technique that enhances statistical power and granularity beyond conventional meta-analyses relying on published summary results. This method allowed for more detailed subgroup analyses, providing high-resolution insights into which patients benefit from hormone therapy and under which clinical circumstances. International collaboration through the MARCAP Consortium was integral to this success, exemplifying the value of cooperative data sharing in advancing cancer research.

Ongoing investigations seek to build on these results by integrating molecular and genetic biomarkers to further refine patient selection for hormone therapy post-prostatectomy. Trials such as the BALANCE Trial aim to unravel the biological underpinnings determining hormone therapy responsiveness, promising even more tailored treatment strategies in the future. Such advancements could revolutionize the management of prostate cancer by combining clinical indicators like PSA with molecular signatures to maximize treatment efficacy while safeguarding patient quality of life.

This pioneering study marks a significant step forward in prostate cancer treatment, encouraging clinicians to reconsider the routine use of hormone therapy in all post-operative radiotherapy cases. By identifying which subsets of patients truly benefit, it is possible to enhance survival outcomes selectively, reduce unnecessary toxicity, and pave the way for personalized medicine in urologic oncology. As further research refines these findings, patients and providers alike may anticipate smarter, less burdensome treatment paradigms that optimize both longevity and well-being.

In summary, the evidence emerging from this meta-analysis robustly supports the notion that hormone therapy should not be indiscriminately combined with post-operative radiotherapy, particularly in men with low PSA levels where radiotherapy alone suffices. For those with higher PSA levels, hormone therapy remains a valuable adjunct, although the optimal duration continues to be an open question. These insights hold promise for reshaping clinical guidelines, highlighting the centrality of PSA stratification in therapeutic decision-making and exemplifying the ongoing evolution toward precision oncology.

Subject of Research: Prostate cancer treatment optimization following prostatectomy
Article Title: Hormone Therapy Addition to Post-Prostatectomy Radiotherapy Provides Limited Survival Benefit Except for High PSA Patients
News Publication Date: 2024
Web References:

• The Lancet Article
• BALANCE Trial
  References: Published study in The Lancet, MARCAP Consortium clinical trial data
  Keywords: Prostate cancer, hormone therapy, androgen deprivation therapy, radiotherapy, PSA levels, post-operative treatment, metastasis-free survival, personalized oncology, cancer treatment side effects, randomized controlled trials, meta-analysis, BALANCE trial